FeesSafety
Pluang+

EU approves Sanofi's next-gen rabies vaccine VaxRabeo for all ages, enhancing prevention and treatment options.

Market News
19 Nov 2026, 08:00 WIB
GlobeNewsWire
View Source
Bullish
EU approves Sanofi's next-gen rabies vaccine VaxRabeo for all ages, enhancing prevention and treatment options.

Sanofi's new rabies vaccine, VaxRabeo, has received European Commission approval for use in all age groups for both pre-exposure and post-exposure prophylaxis. The vaccine uses advanced Vero-cell technology, offering improved safety, longer shelf life, and better stability compared to existing vaccines. Rabies remains a deadly disease with no cure once symptoms appear, making vaccination critical. VaxRabeo's approval marks a significant advancement in rabies prevention, supported by clinical trials showing comparable effectiveness and safety to current vaccines.

Sanofi SA (SNY) trades at USD 47.01 on Pluang as of Nov 19, 2026 13:01 WIB, down 1.09% in the last day. The company holds a market cap of $114.30 billion and offers a dividend yield of 5.09%. This price movement comes as Sanofi announces EU approval for its next-generation rabies vaccine, VaxRabeo, a notable development in its health sector portfolio.

More News (SNY)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App